Drug Trial Radar · NCT06972849
Caffeine Citrate to Improve Neonatal Outcomes.
Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
3,900
Planned (sponsor's estimate)
Start
Oct 2025
Primary completion
Dec 2029
Study completion Dec 2050
Sponsor
- Lead sponsor
- University of MelbourneAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 15, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 32 weeks
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial to learn what dose/s of caffeine citrate works to treat preterm born babies who have episodes where they stop breathing. It will also learn about the safety of different doses of caffeine citrate for the variety of preterm-born babies that are prescribed this. The main question it aims to answer is: Which dose is the optimal dose of caffeine citrate for very preterm babies to prevent short-term death and disease? Researchers will compare three different doses of caffeine citrate, which are already used in clinical practice to treat breathing stoppages in preterm babies, to see which dose works best. No placebo will be used. Participants will be given a 'loading' dose of caffeine citrate \<72 hours of life, and a smaller 'maintenance' dose once a day, for as long as the baby needs this. This trial will be undertaken as part of the PLATIPUS trial (NCT06461429).
Conditions
- Apnea of Prematurity
Interventions
Caffeine citrateDrug
Clinically indicated for apnea of prematurity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who progress by at least one level higher on the PLATIPUS Ordinal Outcome ScaleTime frame: At any time prior to 42 weeks' postmenstrual age or first discharge home from hospital (whichever is earlier)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.